An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Phase of Trial: Phase II/III
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Bavituximab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Peregrine Pharmaceuticals
- 07 Jul 2017 Status changed from suspended to discontinued.
- 13 Apr 2016 This trial was prematurely terminated in Germany, according to the European Clinical Trials Database.
- 08 Mar 2016 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.